Alfresa Holdings Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALFRY research report →
Companywww.alfresa.com
Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. It is involved in the ethical pharmaceuticals wholesaling business that offers diagnostic reagents and medical devices/equipment to hospitals, clinics, and dispensing pharmacies. The company also engages in self-medication products wholesaling business that offers over-the-counter drugs, including health foods, supplements, and other products to drug stores and pharmacies.
- CEO
- Ryuji Arakawa
- IPO
- 2018
- Employees
- 12,517
- HQ
- Tokyo, JP
Price Chart
Valuation
- Market Cap
- $2.62B
- P/E
- 9.80
- P/S
- 0.13
- P/B
- 0.81
- EV/EBITDA
- 4.91
- Div Yield
- 3.02%
Profitability
- Gross Margin
- 7.02%
- Op Margin
- 1.17%
- Net Margin
- 1.34%
- ROE
- 8.48%
- ROIC
- 4.28%
Growth & Income
- Revenue
- $3.29T · 11.15%
- Net Income
- $44.26B · 61.61%
- EPS
- $242.87 · 64.61%
- Op Income
- $38.19B
- FCF YoY
- 257.15%
Performance & Tape
- 52W High
- $16.81
- 52W Low
- $12.42
- 50D MA
- $16.05
- 200D MA
- $15.54
- Beta
- -0.12
- Avg Volume
- 143
Get TickerSpark's AI analysis on ALFRY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ALFRY Coverage
We haven't published any research on ALFRY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALFRY Report →